Acquired Resistance to KRAS G12C Inhibition in Cancer

Authors: Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa L. Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Joseph O. Jacobson, Xiaoping Yang, Nicole S. Persky, David E. Root, Kristen E. Lowder, Hanrong Feng, Shannon S. Zhang, Kevin M. Haigis, Yin P. Hung, Lynette M. Sholl, Brian M. Wolpin, Julie Wiese, Jason Christiansen, Jessica Lee, Alexa B. Schrock, Lee P. Lim, Kavita Garg, Mark Li, Lars D. Engstrom, Laura Waters, J. David Lawson, Peter Olson, Piro Lito, Sai-Hong I. Ou, James G. Christensen, Pasi A. Jänne, Andrew J. Aguirre - New England Journal of Medicine, NEJM 2021 cited by 1,164

BACKGROUND: ). The mechanisms of acquired resistance to these therapies are currently unknown. METHODS: inhibitors. RESULTS: inhibitors. CONCLUSIONS: inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer. (Funded by Mirati Therapeutics and others; ClinicalTrials.gov number, NCT03785249.).